Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
It'll become increasing cloudy tonight, with outbreaks of rain in the northwest
Six months on from the referendum, Political Editor Robert Peston takes a road trip to find out what people feel about Brexit now.
Donald Trump has been criticised for appointing a man who once sued the Environmental Protection Agency to be its new boss.